John B. Miller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
John B. Miller has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
John N. Aucott
Rheumatology Division, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, USA
5 shared publicationsAlison W. Rebman
Rheumatology Division, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, USA
3 shared publicationsAlan N. Baer
Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. The research reported in this publication was supported in part by the Cupid Foundation to JBM. The authors declare no conflicts of interest. Address correspondence to Dr. J.B. Miller, Instructor of Medicine, 5200 Eastern Ave., Mason F. Lord Building Center Tower, Suite 4100, Baltimore, MD 21224, USA.
2 shared publications- Allan Charles Gelber
Thayer Firm, Osler Medical Service, Johns Hopkins Hospital, Baltimore
2 shared publications - Alexander Joseph Ambinder
Department of Oncology Johns Hopkins University Baltimore Maryland USA
1 shared publication Alison Rebman
Department of Medicine, Johns Hopkins University, Baltimore, USA
1 shared publication
Latest Publications
- Open Access
- 29 August 2026
- Published by Springer Nature in Scientific Reports
Longitudinal serum proteomics identifies candidate immune, coagulation, and metabolic signatures associated with post-treatment Lyme disease
- 29 August 2026
- Published by Springer Nature in Scientific Reports
Open AccessLongitudinal serum proteomics identifies candidate immune, coagulation, and metabolic signatures associated with post-treatment Lyme disease
- Open Access
- 30 September 2025
- Published by Springer Nature in BMC Rheumatology
- Vol. 9 (1) , 1-5
Non-radiographic axial spondyloarthritis developing after Lyme arthritis: a case report and review
Lyme disease is a tick-borne illness that can result in a spectrum of musculoskeletal complications, ranging from infection-related arthritis to post-infectious, immune-mediated conditions. Although prior reports have linked Lyme disease to systemic autoimmune diseases, such as rheumatoid arthritis and psoriatic arthritis, non-radiographic axial spondyloarthritis (nr-axSpA) has not previously been described following Lyme disease. A previously healthy patient developed monoarthritis of the ankle, with inflammatory synovial fluid and a positive Lyme Western blot, consistent with Lyme arthritis. Symptoms resolved after antimicrobial therapy. However, he subsequently developed new-onset inflammatory back pain, with symptoms persisting despite several courses of antibiotics. Examination revealed sacroiliac joint tenderness and a positive Flexion Abduction and External Rotation (FABER) test. Imaging demonstrated bilateral sacroiliitis, with multifocal bone marrow edema and subcortical erosions on MRI. HLA-B27 was positive, meeting classification criteria for nr-axSpA. Treatment with Adalimumab led to marked clinical improvement. Previous studies have described sacroiliitis in the context of active infection, though this case represents a novel association between Lyme disease and nr-axSpA. This case suggests that Lyme disease may be a potential trigger for nr-axSpA in genetically predisposed individuals and expands the spectrum of infection-associated autoimmunity. Clinicians should consider nr-axSpA in patients with persistent inflammatory back pain following Lyme disease.
- 30 September 2025
- Published by Springer Nature in BMC Rheumatology
- Vol. 9 (1) , 1-5
Open AccessNon-radiographic axial spondyloarthritis developing after Lyme arthritis: a case report and review
Lyme disease is a tick-borne illness that can result in a spectrum of musculoskeletal complications, ranging from infection-related arthritis to post-infectious, immune-mediated conditions. Although prior reports have linked Lyme disease to systemic autoimmune diseases, such as rheumatoid arthritis and psoriatic arthritis, non-radiographic axial spondyloarthritis (nr-axSpA) has not previously been described following Lyme disease. A previously healthy patient developed monoarthritis of the ankle, with inflammatory synovial fluid and a positive Lyme Western blot, consistent with Lyme arthritis. Symptoms resolved after antimicrobial therapy. However, he subsequently developed new-onset inflammatory back pain, with symptoms persisting despite several courses of antibiotics. Examination revealed sacroiliac joint tenderness and a positive Flexion Abduction and External Rotation (FABER) test. Imaging demonstrated bilateral sacroiliitis, with multifocal bone marrow edema and subcortical erosions on MRI. HLA-B27 was positive, meeting classification criteria for nr-axSpA. Treatment with Adalimumab led to marked clinical improvement. Previous studies have described sacroiliitis in the context of active infection, though this case represents a novel association between Lyme disease and nr-axSpA. This case suggests that Lyme disease may be a potential trigger for nr-axSpA in genetically predisposed individuals and expands the spectrum of infection-associated autoimmunity. Clinicians should consider nr-axSpA in patients with persistent inflammatory back pain following Lyme disease.
- Open Access
- 16 July 2025
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 74, 152797
Estimating the incidence of autoimmune inflammatory arthritis after Lyme disease
- 16 July 2025
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 74, 152797
Open AccessEstimating the incidence of autoimmune inflammatory arthritis after Lyme disease
- Open Access
- 18 April 2025
- Published by Springer Nature in Cureus
- Vol. 17 (4)
Prevalence of Rheumatoid Factor and Anti-citrullinated Protein Antibodies in Patients With Post-treatment Lyme Disease
Post-treatment Lyme disease (PTLD) occurs in a portion of patients after initial antibiotic treatment of Lyme disease (LD) and is often characterized by arthralgia without synovitis. Rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) are often used to assess joint pain in this setting; however, their clinical utility remains unknown. Our objective was to define the frequency of these autoantibodies in a large cohort of carefully characterized patients with PTLD meeting a research case definition and to determine the clinical implications of these tests. RF and ACPA were tested as indicated clinically and abstracted by chart review. The prevalence of antibodies and their relationship to symptoms were examined. Of the 167 patients included in the analysis, RF status was documented at least once for 78.4% (131 of 167), and ACPA status was available at least once for 88.0% (147 of 167). RF was positive in 3.8% (five of 131), and ACPA was positive in 4.8% (seven of 147) at least at one time point. A total of 7.2% (12 of 167) patients were found to have a positive RF or ACPA test at least at one time point. There was no difference in the proportion of patients with RF and/or ACPA based on the initial presenting manifestations of their LD, nor the symptoms of PTLD at later evaluation; however, the small sample size may limit our ability to detect these clinical differences. We found a low prevalence of RF and ACPA in this study, similar to the known rates in the general population. This reflects the lack of inflammatory arthritis in this population with clinically defined PTLD and arthralgia only.
- 18 April 2025
- Published by Springer Nature in Cureus
- Vol. 17 (4)
Open AccessPrevalence of Rheumatoid Factor and Anti-citrullinated Protein Antibodies in Patients With Post-treatment Lyme Disease
Post-treatment Lyme disease (PTLD) occurs in a portion of patients after initial antibiotic treatment of Lyme disease (LD) and is often characterized by arthralgia without synovitis. Rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) are often used to assess joint pain in this setting; however, their clinical utility remains unknown. Our objective was to define the frequency of these autoantibodies in a large cohort of carefully characterized patients with PTLD meeting a research case definition and to determine the clinical implications of these tests. RF and ACPA were tested as indicated clinically and abstracted by chart review. The prevalence of antibodies and their relationship to symptoms were examined. Of the 167 patients included in the analysis, RF status was documented at least once for 78.4% (131 of 167), and ACPA status was available at least once for 88.0% (147 of 167). RF was positive in 3.8% (five of 131), and ACPA was positive in 4.8% (seven of 147) at least at one time point. A total of 7.2% (12 of 167) patients were found to have a positive RF or ACPA test at least at one time point. There was no difference in the proportion of patients with RF and/or ACPA based on the initial presenting manifestations of their LD, nor the symptoms of PTLD at later evaluation; however, the small sample size may limit our ability to detect these clinical differences. We found a low prevalence of RF and ACPA in this study, similar to the known rates in the general population. This reflects the lack of inflammatory arthritis in this population with clinically defined PTLD and arthralgia only.
- Open Access
- 22 November 2024
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 31 (2) , 65-70
Anti-RA33 Antibodies Are Present in Patients With Lyme Disease
Background/Objective: To determine if anti-RA33 antibodies, which can be seen in early forms of inflammatory arthritis, are present in patients with Lyme arthritis (LA). Methods: Anti-RA33 antibodies were tested using a commercially available assay in patients with LA (n = 47) and compared with patients with erythema migrans who returned to health (EM RTH, n = 20) and those with post-treatment Lyme disease (PTLD) (n = 50), characterized by noninflammatory arthralgia, as an observational comparative study utilizing Lyme-exposed patients from various original cohorts. Results: We found that anti-RA33 was present in higher proportions of patients with LA (23.4% vs. 0%, p = 0.001) and PTLD (12.0% vs. 0%, p = 0.040) than healthy controls. There was also a trend toward a higher percentage of anti-RA33 positivity in patients with EM RTH versus controls (10.0% vs. 0%, p = 0.080). There were no statistically significant differences among groups of patients with LA, PTLD, and EM RTH (p ≥ 0.567). There was also no difference in the proportion of patients with antibiotic-responsive LA compared with those with persistent synovitis after antibiotics, termed post-infectious LA, and there were no differences in clinical manifestations, musculoskeletal ultrasound evaluation (synovial hypertrophy, power Doppler, tendinopathy), or patient-reported outcomes based on anti-RA33 status. Conclusions: This is the first study to identify anti-RA33 antibodies in patients with LA, though these antibodies did not identify a unique clinical subset of patients in this cohort. Unexpectedly, we found anti-RA33 antibodies at similar levels in patients with PTLD and EM RTH; further study is needed to determine the relevance of this finding.
- 22 November 2024
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 31 (2) , 65-70
Open AccessAnti-RA33 Antibodies Are Present in Patients With Lyme Disease
Background/Objective: To determine if anti-RA33 antibodies, which can be seen in early forms of inflammatory arthritis, are present in patients with Lyme arthritis (LA). Methods: Anti-RA33 antibodies were tested using a commercially available assay in patients with LA (n = 47) and compared with patients with erythema migrans who returned to health (EM RTH, n = 20) and those with post-treatment Lyme disease (PTLD) (n = 50), characterized by noninflammatory arthralgia, as an observational comparative study utilizing Lyme-exposed patients from various original cohorts. Results: We found that anti-RA33 was present in higher proportions of patients with LA (23.4% vs. 0%, p = 0.001) and PTLD (12.0% vs. 0%, p = 0.040) than healthy controls. There was also a trend toward a higher percentage of anti-RA33 positivity in patients with EM RTH versus controls (10.0% vs. 0%, p = 0.080). There were no statistically significant differences among groups of patients with LA, PTLD, and EM RTH (p ≥ 0.567). There was also no difference in the proportion of patients with antibiotic-responsive LA compared with those with persistent synovitis after antibiotics, termed post-infectious LA, and there were no differences in clinical manifestations, musculoskeletal ultrasound evaluation (synovial hypertrophy, power Doppler, tendinopathy), or patient-reported outcomes based on anti-RA33 status. Conclusions: This is the first study to identify anti-RA33 antibodies in patients with LA, though these antibodies did not identify a unique clinical subset of patients in this cohort. Unexpectedly, we found anti-RA33 antibodies at similar levels in patients with PTLD and EM RTH; further study is needed to determine the relevance of this finding.
- 1 March 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (3) , 1111-1121
Characteristics associated with patient-reported treatment success in psoriatic arthritis
To determine characteristics associated with patient-reported treatment success in psoriatic arthritis (PsA). Rheumatologist-diagnosed PsA patients fulfilling the CASPAR classification were recruited from a single center. PsA outcome measures included: 66/68 swollen/tender joint counts, Leeds/SPARCC dactylitis/enthesitis indices, psoriasis body surface area (BSA), and patient-reported outcomes (PROs) including PROMIS. The primary outcome was a patient-reported item: “Today, considering the level of control of your psoriatic arthritis and psoriasis, do you consider your treatment has been successful?” Descriptive and multivariate logistic regression analyses identified clinical predictors of patient-reported treatment success. Patient-reported reasons for lack of treatment success were explored. A total of 178 participants had a baseline visit. Mean (SD) CASPAR score was 3.7 (0.9), age 51.7 (13.5) years, and BMI 31.3 (7.2) kg/m2. Fifty-two percent were women, and 86.0% white. Treatment success was reported by 116/178(65%) patients in the analytic cohort. Among 76 patients who reported treatment failure, the most frequently selected reasons for lack of success were pain (n = 55, 72.4%), fatigue (n = 46, 60.5%), inflamed joints (n = 40, 52.6%), and stiffness (n = 40, 52.6%). Overall, 105 participants had complete data across variables in the logistic regression models. Patient-reported treatment success was independently associated with the 66-swollen/68-tender joint counts, psoriasis BSA, PROs (pain interference, physical function, fatigue), and TNF-inhibitor therapy, after controlling for BMI and demographics. Patient-reported treatment success in PsA may be achieved through improvement of inflammatory arthritis, psoriasis, pain, physical function, fatigue, and the use ofTNF-inhibitors. Patients reported treatment failure was most commonly due to symptoms of pain, fatigue and stiffness.
- 1 March 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (3) , 1111-1121
Characteristics associated with patient-reported treatment success in psoriatic arthritis
To determine characteristics associated with patient-reported treatment success in psoriatic arthritis (PsA). Rheumatologist-diagnosed PsA patients fulfilling the CASPAR classification were recruited from a single center. PsA outcome measures included: 66/68 swollen/tender joint counts, Leeds/SPARCC dactylitis/enthesitis indices, psoriasis body surface area (BSA), and patient-reported outcomes (PROs) including PROMIS. The primary outcome was a patient-reported item: “Today, considering the level of control of your psoriatic arthritis and psoriasis, do you consider your treatment has been successful?” Descriptive and multivariate logistic regression analyses identified clinical predictors of patient-reported treatment success. Patient-reported reasons for lack of treatment success were explored. A total of 178 participants had a baseline visit. Mean (SD) CASPAR score was 3.7 (0.9), age 51.7 (13.5) years, and BMI 31.3 (7.2) kg/m2. Fifty-two percent were women, and 86.0% white. Treatment success was reported by 116/178(65%) patients in the analytic cohort. Among 76 patients who reported treatment failure, the most frequently selected reasons for lack of success were pain (n = 55, 72.4%), fatigue (n = 46, 60.5%), inflamed joints (n = 40, 52.6%), and stiffness (n = 40, 52.6%). Overall, 105 participants had complete data across variables in the logistic regression models. Patient-reported treatment success was independently associated with the 66-swollen/68-tender joint counts, psoriasis BSA, PROs (pain interference, physical function, fatigue), and TNF-inhibitor therapy, after controlling for BMI and demographics. Patient-reported treatment success in PsA may be achieved through improvement of inflammatory arthritis, psoriasis, pain, physical function, fatigue, and the use ofTNF-inhibitors. Patients reported treatment failure was most commonly due to symptoms of pain, fatigue and stiffness.
- Open Access
- 1 January 2024
- Published by SAGE Publications in Therapeutic Advances in Infectious Disease
- Vol. 11
Annexin A2 antibodies in post-treatment Lyme disease
Background: Anti-annexin A2 (AA2) antibodies have been described in Lyme arthritis and erythema migrans, although they have not been described in post-treatment Lyme disease (PTLD). Objectives: Determine whether anti-AA2 antibodies are present among patients with PTLD and determine the clinical relevance of these antibodies. Design and methods: Anti-AA2 levels were tested serially in a longitudinal cohort of 44 patients with acute Lyme disease, 22 with a return to health (EM RTH), and 22 with PTLD. Anti-AA2 antibodies were also assessed in a cross-sectional group of 281 patients with PTLD. Results: Anti-AA2 antibodies were highest after antimicrobial therapy in both the EM RTH and PTLD cohorts. By 6 months, there was no difference between EM RTH and healthy controls. Anti-AA2 antibodies were higher in the cross-sectional PTLD group (79.69 versus 48.22 units, p < 0.0001), though with no difference in total symptom burden. Conclusion: Anti-AA2 persists in PTLD, though did not identify a clinical phenotype.
- 1 January 2024
- Published by SAGE Publications in Therapeutic Advances in Infectious Disease
- Vol. 11
Open AccessAnnexin A2 antibodies in post-treatment Lyme disease
Background: Anti-annexin A2 (AA2) antibodies have been described in Lyme arthritis and erythema migrans, although they have not been described in post-treatment Lyme disease (PTLD). Objectives: Determine whether anti-AA2 antibodies are present among patients with PTLD and determine the clinical relevance of these antibodies. Design and methods: Anti-AA2 levels were tested serially in a longitudinal cohort of 44 patients with acute Lyme disease, 22 with a return to health (EM RTH), and 22 with PTLD. Anti-AA2 antibodies were also assessed in a cross-sectional group of 281 patients with PTLD. Results: Anti-AA2 antibodies were highest after antimicrobial therapy in both the EM RTH and PTLD cohorts. By 6 months, there was no difference between EM RTH and healthy controls. Anti-AA2 antibodies were higher in the cross-sectional PTLD group (79.69 versus 48.22 units, p < 0.0001), though with no difference in total symptom burden. Conclusion: Anti-AA2 persists in PTLD, though did not identify a clinical phenotype.
- 21 July 2023
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
- Vol. 42 (7) , 1487-1490
Autoantibodies in post-treatment Lyme disease and association with clinical symptoms
Brief Papers; Authors: M. Keshtkarjahromi, A.W. Rebman, A.A. Antar, Y.C. Manabe, L. Gutierrez-Alamillo, L.A. Casciola-Rosen, J.N. Aucott, J.B. Miller
- 21 July 2023
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
- Vol. 42 (7) , 1487-1490
Autoantibodies in post-treatment Lyme disease and association with clinical symptoms
Brief Papers; Authors: M. Keshtkarjahromi, A.W. Rebman, A.A. Antar, Y.C. Manabe, L. Gutierrez-Alamillo, L.A. Casciola-Rosen, J.N. Aucott, J.B. Miller
- 2 May 2022
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 241, 139-144
Scleritis in Lyme Disease
- 2 May 2022
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 241, 139-144
Scleritis in Lyme Disease
- 15 January 2021
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 48 (5) , 788.1-789
Hyperviscosity Syndrome in Rheumatoid Arthritis
Hyperviscosity syndrome (HVS) is a life-threatening condition often occurring as a complication of Waldenström macroglobulinemia (WM) but rarely in the context of rheumatic disease. Given its rarity, diagnosis can be delayed, leading to greater morbidity.
- 15 January 2021
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 48 (5) , 788.1-789
Hyperviscosity Syndrome in Rheumatoid Arthritis
Hyperviscosity syndrome (HVS) is a life-threatening condition often occurring as a complication of Waldenström macroglobulinemia (WM) but rarely in the context of rheumatic disease. Given its rarity, diagnosis can be delayed, leading to greater morbidity.